Recent developments highlight clinical trial progress, analyst buy recommendations, and insider buying activity, alongside regulatory compliance challenges.

• Alzamend Neuro announced data from its Phase II clinical trial of AL001, the 'Lithium In Brain' study, indicating ongoing clinical development progress [N2].
• The company planned Phase II clinical studies of AL001 for bipolar disorder and major depressive disorder, with the bipolar disorder study expected to start in Q3 2025 [N8].
• Ascendiant Capital maintained a buy recommendation on Alzamend Neuro, reflecting positive analyst sentiment [N5].
• Insider buying activity was reported in April 2026, indicating insider confidence in the company [N1].
• The company reported net cash gained by financing activities of $8.3 million as of December 2024, supporting liquidity [N13].
• Nasdaq issued a notice of non-compliance due to stockholders’ equity below the minimum requirement, and the company is preparing a plan to regain compliance [S13].

The company has demonstrated clinical progress with Phase II data releases and ongoing studies for AL001 in bipolar disorder and major depressive disorder, which could validate its lithium delivery approach. Positive analyst coverage and insider buying suggest confidence in the company's strategy and potential. If clinical trials confirm efficacy and safety, AL001 could address significant unmet needs in neurological and psychiatric treatment, supporting future growth opportunities.

Alzamend Neuro faces significant financial challenges, including net losses and liquidity constraints, with a current ratio below 1 and cash ratio under 0.2, indicating potential funding needs. The company is currently non-compliant with Nasdaq's minimum stockholders' equity requirement, risking delisting if compliance is not regained. Clinical development risks, regulatory uncertainties, and the absence of commercial products add to the operational risks. Failure to secure additional funding or clinical setbacks could materially impact the company's viability.

Alzamend Neuro's moat is primarily based on its proprietary lithium delivery technology, AL001, which targets brain disorders with a novel approach. The company's clinical trial progress and intellectual property around AL001 contribute to its competitive positioning. However, as a clinical-stage company without commercial products, its moat is contingent on successful clinical development and regulatory approval, which remain uncertain and subject to clinical and regulatory risks.

• Nasdaq Listing Compliance Risk: The company’s stockholders’ equity was below Nasdaq Capital Market requirements as of January 31, 2026, leading to a notice of non-compliance and a deadline to submit a plan to regain compliance. Failure to meet listing standards could result in delisting.
• Liquidity and Financial Risk: As of April 30, 2026, the company had limited cash and current assets relative to current liabilities, with liquidity ratios indicating potential funding challenges. Continued net losses increase the need for additional capital.
• Clinical Development Risk: The company’s business depends on successful clinical trials of AL001. Clinical trial outcomes, regulatory approvals, and market acceptance are uncertain and could adversely affect the business.
• Market and Operational Risks: The company faces risks from competition, regulatory changes, and operational execution. The disclosed risk factors in the 2025 Annual Report remain current and highlight material uncertainties.

• Alzamend Neuro, Inc. is a Delaware corporation headquartered in Atlanta, Georgia, trading on The Nasdaq Capital Market under the ticker ALZN [S4,S5,S6].
• The company is engaged in clinical development of AL001, a lithium delivery product targeting neurological and psychiatric disorders, including bipolar disorder and major depressive disorder [N2,N8,N9].
• Alzamend Neuro has announced data from a Phase II clinical trial of AL001, referred to as the 'Lithium In Brain' study [N2].
• The company planned and announced Phase II clinical studies of AL001 for bipolar disorder and major depressive disorder, with the bipolar disorder study expected to start in Q3 2025 [N8,N9].
• Alzamend Neuro reported net cash gained by financing activities amounting to $8.3 million as of December 2024 [N13].
• The company reported a net loss of $8.77 million for the fiscal year ended April 30, 2026, with basic and diluted EPS of -$2.63 per share [S1].
• As of April 30, 2026, Alzamend Neuro had cash and cash equivalents of approximately $710,689 and current assets of about $1.76 million [S1].
• The company’s current liabilities were reported as approximately $3.83 million as of January 31, 2024, resulting in a current ratio of 0.46 and a cash ratio of 0.19 as of April 30, 2026, indicating liquidity constraints [S1].
• Alzamend Neuro’s stockholders’ equity was approximately $2.2 million as of January 31, 2026, below the Nasdaq Capital Market minimum requirement of $2.5 million, leading to a Nasdaq notice of non-compliance and a plan submission deadline to regain compliance [S13,S14].
• The company is an emerging growth company and has ongoing efforts to regain Nasdaq listing compliance [S13].
• Risk factors disclosed in the 2025 Annual Report on Form 10-K remain current and include material risks that could adversely affect the business, financial condition, and stock price [S2].
• Analyst coverage includes buy recommendations from Ascendiant Capital and Maxim Group, reflecting positive views on the company’s clinical progress and product momentum [N5,N7,N15].
• Recent insider buying activity was reported in April 2026 [N1].